RoboPharma is an EU-funded initiative led by CurifyLabs (Finland), focused on developing a decentralized pharmaceutical manufacturing platform using artificial intelligence and robotics to strengthen Europe’s medicine supply chain and crisis preparedness.
AtrimusRx AB participates as a partner in the RoboPharma consortium, together with organizations across Europe, including Fysioline Oy, Pharmacie Delpech, Tartu University Hospital, University Medical Center Mainz and Vaasa Hietalahti Pharmacy.
The project develops an agile manufacturing platform for pharmacies and hospital pharmacies, integrating AI-driven analytics, robotic dosing technologies, RFID tracking and automated workflows. The aim is to enable real-time, scalable and regulatory-compliant production of essential medicines, particularly in situations of medicine shortages or supply chain disruptions.
Project locations include Finland, Sweden, France, Estonia and Germany.
EU contribution: €3.36 million
Funding programme: EU4Health (2021–2027)
Read more about the project here:
https://strategic-technologies.europa.eu/step-results/step-stories/robopharma_en
RoboPharma, led by CurifyLabs (Finland), is a €5.6 million EU-funded initiative developing an AI- and robotics-driven decentralized pharmaceutical manufacturing platform. Funded through the EU4Health programme, the project strengthens Europe’s healthcare resilience by enabling hospitals and pharmacies to locally produce essential and personalized medicines. Together with partners across Europe — Delpech Pharmacy, AtrimusRx, Vaasa Hietalahti Pharmacy, Tartu University Hospital, Fysioline, and University Medical Center Mainz — RoboPharma is shaping a more flexible, patient-centric, and crisis-ready pharmaceutical future.
*Co-funded by the European Union. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA: Neither the European Union nor the granting authority can be held responsible for them.